This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56
lck
tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
本发明涉及抑制血小板源性生长因子或p56lck
酪氨酸激酶活性的
喹啉/喹噁啉化合物,以及包含这些化合物的制药组合物,以及使用这些化合物治疗患有或患有涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/症状的患者。